Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
复制标题
DOI：
10.1186/s12885-021-08124-9
复制
发表时间：
2021-05-18
期刊：
影响因子：
3.8
通讯作者：
Cho M
中科院分区：
文献类型：
--
作者：
Hong YM;Yoon KT;Cho M
Regorafenib作为索拉非尼进展的肝细胞癌（HCC）患者的二线治疗显示出有希望的结果。虽然有一些关于sorafenib序贯治疗和regorafenib在现实生活中的疗效的数据，但预测预后的特异性炎症标志物尚未研究。本研究旨在探讨全身性炎症标志物在接受索拉非尼-瑞非尼序贯治疗的HCC患者中的预后价值。我们回顾性分析索拉非尼失败后接受瑞非尼治疗HCC患者的医疗资料。采用Kaplan-Meier生存曲线评估无进展生存期（PFS）和总生存期（OS）。进行单因素和多因素分析，分析与生存相关的因素。共有58例患者接受了至少一剂regroafenib，符合资格标准，表现良好（东部肿瘤合作组[ECOG] 0-1），肝功能保存（Child-Pugh-A）。中位PFS为3个月（95%可信区间[CI] = 0.981 ~ 5.019），中位OS为8个月（95% CI = 5.761 ~ 10.239）。全身免疫炎症指数升高（SII≥340）与不良OS独立相关。多因素分析中，SII（风险比[HR] = 2.211, 95% CI = 1.089 ~ 4.489, P = 0.028）和甲胎蛋白（AFP）（风险比[HR] = 2.750, 95% CI = 1.259 ~ 6.010, P = 0.011）是OS的独立预测因子。在接受索拉非尼和瑞非尼序期治疗的HCC患者中，SII升高与不良OS相关。此外，在选择治疗策略时，SII可与AFP水平联合使用，作为HCC的预后工具。
Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although there have been several data regarding the efficacy of sequential therapy with sorafenib and that of regorafenib in real-life, specific inflammation markers for predicting the prognosis have not been studied. This study aimed to investigate prognostic value of systemic inflammatory markers in patients with HCC who received sorafenib-regorafenib sequential therapy. We retrospectively analyzed medical data of patients who received regorafenib for the treatment of HCC after sorafenib failure. Progression free survival (PFS) and overall survival (OS) were assessed using the Kaplan–Meier survival curves. Univariate and multivariate analyses were performed to analyze the factors associated with survival. A total of 58 patients who received at least one dose of regroafenib and fulfilled the eligibility criteria, good performance status (Eastern Cooperative Oncology Group [ECOG] 0–1) and preserved liver function (Child-Pugh-A), were included in the analysis. The median PFS was 3 months (95% confidence interval [CI] = 0.981–5.019) and the median OS was 8 months (95% CI = 5.761–10.239). Elevated systemic immune-inflammation index (SII ≥340) was independently associated with poor OS. In multivariate analysis, the SII (hazard ratio [HR] = 2.211, 95% CI = 1.089–4.489, P = 0.028) and alpha-fetoprotein (AFP) (HR = 2.750, 95% CI = 1.259–6.010, P = 0.011) were independent predictors of OS. Elevated SII is associated with poor OS in patients with HCC who received sequential therapy with sorafenib and regorafenib. In addition, when selecting a treatment strategy, the SII can be used in combination with the AFP level as a promising prognostic tool for HCC.
登录
查看更多内容
影响因子：
--
作者：
Casadei Gardini A;Scarpi E;Faloppi L;Scartozzi M;Silvestris N;Santini D;de Stefano G;Marisi G;Negri FV;Foschi FG;Valgiusti M;Ercolani G;Frassineti GL
通讯作者：
Frassineti GL
预处理血小板与淋巴细胞比预测宫颈癌患者的临床结局：一项荟萃分析。
影响因子：
1.6
作者：
Ma JY;Ke LC;Liu Q
通讯作者：
Liu Q
影响因子：
158.5
作者：
Llovet, Josep M.;Ricci, Sergio;Bruix, Jordi
通讯作者：
Bruix, Jordi
DOI：
10.1038/nrc3004
发表时间：
2011-03
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Gay LJ;Felding-Habermann B
通讯作者：
Felding-Habermann B
影响因子：
168.9
作者：
Bruix, Jordi;Qin, Shukui;Han, Guohong
通讯作者：
Han, Guohong